[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
[HTML][HTML] Antibody evasion properties of SARS-CoV-2 Omicron sublineages
The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 14 July 2022
World Health Organization - 2022 - apps.who.int
As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …
Antibodies to combat viral infections: development strategies and progress
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
COVID-19: challenges of viral variants
The COVID-19 pandemic has been accompanied by SARS-CoV-2 evolution and
emergence of viral variants that have far exceeded initial expectations. Five major variants of …
emergence of viral variants that have far exceeded initial expectations. Five major variants of …
Delta variant (B. 1.617. 2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
M Dhawan, A Sharma, N Priyanka… - Human vaccines & …, 2022 - Taylor & Francis
Since commencement of COVID-19 pandemic, several SARS-CoV-2 variants have emerged
amid containment efforts via vaccination. The Delta variant (B. 1.617. 2), discovered in …
amid containment efforts via vaccination. The Delta variant (B. 1.617. 2), discovered in …
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …
Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019
JI Hogan, R Duerr, D Dimartino, C Marier… - Clinical Infectious …, 2023 - academic.oup.com
New mutations conferring resistance to SARS-CoV-2 therapeutics have important clinical
implications. We describe the first cases of an independently acquired V792I RNA …
implications. We describe the first cases of an independently acquired V792I RNA …